PDF herunterladen
Zeitschrift für Phytotherapie 2014; 35(05): 215-218
DOI: 10.1055/s-0034-1371745
Forschung
Passionsblume
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Wirkmechanismus der Passionsblume aufgeklärt

Christine Hoffmann
,
Inga Trompetter
,
Gabriele Weiß
Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Oktober 2014 (online)

   Lizenzen und Reprints

Zusammenfassung

Die Passionsblume wird seit mehreren Jahrhunderten in der Behandlung stressbedingter Symptome eingesetzt. Im den letzten 10 Jahren wurde die Wirksamkeit durch klinische Studien bestätigt, der Wirkmechanismus war aber lange Zeit ungeklärt. Aktuelle Studien zeigen, dass Extrakte aus Passionsblumenkraut die GABA-Wiederaufnahme hemmen, an die GABA-Bindungsstelle des GABAA-Rezeptors binden und nicht mit der Benzodiazepin- und Ethanolbindungsstelle interagieren.

Summary

Passionflower: shedding light on the mechanism of action
Passionflower has been used in the treatment of stress-related symptoms for several centuries. In the last decade the efficacy was proved in clinical studies, however, the mechanism of action was still unclear. Recent non-clinical studies show that passionflower extracts inhibit GABA-reuptake, bind to the GABA binding site of the GABAA- receptor and do not interact with the ethanol or benzodiazepine binding side.

Schlüsselwörter

Passionsblume - Passiflora incarnata L. - Stress - GABA - Benzodiazepine

Key words

Passionflower - Passiflora incarnata L. - stress - GABA - benzodiazepines
 

  • Literatur

  • 1 Akhondzadeh S, Kashani L, Mobaseri M et al. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther 2001; 26: 369-373
    CrossrefPubMedGoogle Scholar
  • 2 Akhondzadeh S, Mohammadi MR, Momeni F. Passiflora incarnata in the treatment of attention- deficit hyperactivity disorder in children and adolescents. Therapy 2005; 2: 609-614
    CrossrefPubMedGoogle Scholar
  • 3 Akhondzadeh S, Naghavi HR, Vazirian M et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001; 26: 363-367
    CrossrefPubMedGoogle Scholar
  • 4 Anagnostou S. Johanniskraut, Baldrian und Passionsblume. Die Geschwister der Seele. Pharm Ztg 156 (48) 2011; 64-70
    PubMedGoogle Scholar
  • 5 Appel K, Rose T, Fiebich B et al. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res 2011; 25: 838-843
    Google Scholar
  • 6 Aslanargun P, Cuvas O, Dikmen B et al. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth 2012; 26: 39-44
    CrossrefPubMedGoogle Scholar
  • 7 Bidlack JM, Parkhill AL. Assay of G proteincoupled receptor activation of G proteins in native cell membranes using [35S]GTP gamma S binding. Methods Mol Biol 2004; 237: 135-143
    PubMedGoogle Scholar
  • 8 Blumenthal M, Goldberg A, Brinkmann J. Herbal Medicine – Expanded Commission E Monographs. Newton, MA: Integrative Medicine Communications; 2000
  • 9 Deutsche Hauptstelle für Suchtfragen e.V. Psychotrope Medikamente. 2012 http://www.dhs.de/datenfakten/medikamente.html .
    PubMed
  • 10 Dimpfel W, Koch K, Weiss G. Single dose effects of Pascoflair® on current source density (CSD) of human EEG. Neuroscience & Medicine 2012; 3: 130-140
    PubMedGoogle Scholar
  • 11 EMA. Note for guidance on the investigation of drug interactions. 1997 CPMP/EWP/560/95.
    PubMedGoogle Scholar
  • 12 EMA. Community herbal monograph on Passiflora incarnata L., herba. Stand 25.3.2014. EMA/HMPC/669740/2013.
    PubMedGoogle Scholar
  • 13 EMA. Guideline on the assessment of genotoxicity of herbal substances/preparations. 2008 EMEA/HMPC/107079/2007.
    PubMedGoogle Scholar
  • 14 ESCOP. Passiflorae herba. Passion flower. ESCOP Monographs. Stuttgart, New York: Thieme; 2003: 359-364
    Google Scholar
  • 15 Gründer G, Benkert O. Handbuch der psychiatrischen Pharmakotherapie. 2. Aufl. Berlin, Heidelberg: Springer; 2012
  • 16 Grundmann O, Wang J, McGregor GP, Butterweck V. Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med 2008; 74: 1769-1770
    Google Scholar
  • 17 Koc J, Poser W. Benzodiazepine: Therapie, Missbrauch und Abhängigkeit. Bremer Ärztejournal 2010; 63 (9) 11-12
    PubMedGoogle Scholar
  • 18 Kommission E.. Passiflorae herba (Passionsblumenkraut). BAnz Nr. 223 1985; v. 30.11..
    PubMedGoogle Scholar
  • 19 Maemoto T, Tada M, Mihara T et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci 2004; 96: 42-52
    CrossrefPubMedGoogle Scholar
  • 20 Movafegh A, Alizadeh R, Hajimohamadi F et al. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg 2008; 106: 1728-1730
    CrossrefPubMedGoogle Scholar
  • 21 Schindler CW, Panlilio LV, Gilman JP et al. Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. Eur J Pharmacol 2010; 633: 44-49
    CrossrefPubMedGoogle Scholar
  • 22 Slattery DA, Desrayaud S, Cryan JF. GABAB receptor antagonist-mediated antidepressant- like behavior is serotonin-dependent. J Pharmacol Exp Ther 2005; 312: 290-296
    PubMedGoogle Scholar